Immune to Cancer: The CRI Blog
-
CICON16: Corrupted by Cancer
Day 2 of CICON16 explored strategies to overcome challenges within the tumor microenvironment.
-
CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints
The latest advances in using new checkpoint drugs to target LAG-3, Nrp1, IL-35R, CD36, and mitochondrial metabolism.
-
CICON16: Cancer Antigens and the Development of Personalized Immunotherapy Approaches
Antigens are the key to effective vaccines and the immune system’s ability to target cancer cells.
-
CICON16: Translating Science Into Survival
This Sunday, we are proud to welcome the top international experts in immunology and immunotherapy to New…
-
Love Is On for $1 Million
Choose to love CRI in the second annual Revlon LOVE IS ON Million Dollar Challenge.
-
CRI Congratulates 2016 Lasker Award Winners
The Albert and Mary Lasker Foundation announced the 2016 recipients of the prestigious Lasker Awards, and CRI congratulates Charles…
-
Immunotherapy Patient Summit Agenda – Announced!
#CRISummit16 promises to be an educational and empowering day for cancer patients and their families.
-
FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer
New hope now exists for patients with advanced head and neck cancer.
-
Cancer Research Institute Featured in New York Times Cover Story on Cancer Immunotherapy
The pioneering work of CRI and its funded scientists are profiled in this special feature from the…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.